Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: iRF System Hepatic Denervation; Device
Lead sponsor: Metavention; Industry
Eligibility: 22 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more

Conditions: Glaucoma, Ocular Hypertension
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Artesia, California • Sacramento, California • Bel Air, Maryland + 5 more

Conditions: Visual Impairment, Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma
Interventions: In-House Developed VR Platform - AMD, DR, Glaucoma, In-House Developed VR Platform - Glaucoma; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma
Interventions: NGENUITY, Conventional microscope; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension
Interventions: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg); Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: nebivolol, Metoprolol; Drug
Lead sponsor: University of Miami; Other
Eligibility: 46 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Arterial Hypertension
Interventions: sapropterin dihydrochloride (6R-BH4); Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Erythrocytosis, Pulmonary Hypertension, Thrombosis
Interventions: Belzutifan; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Hypertension
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Overland Park, Kansas • Willingboro, New Jersey

Conditions: Hypertension
Interventions: QUARTET LDQT, Candesartan; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 2
States / cities: Bloomingdale, Illinois • Chicago, Illinois

Conditions: Hypertension, Blood Pressure, Lifestyle Risk Reduction
Interventions: Home Blood Pressure Monitoring, Telephone Health Coaching; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 39 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: bimatoprost ophthalmic solution 0.01%, travoprost ophthalmic solution 0.004%, latanoprost ophthalmic solution 0.005%; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Rogers, Arkansas

Conditions: Myocardial Infarction, Cerebrovascular Accident, Death, Sudden, Cardiac
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 30 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Esophageal and Gastric Varices, Liver Cirrhosis, Portal Hypertension
Interventions: Timolol Maleate, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2002
U.S. locations: 3
States / cities: New Haven, Connecticut • West Haven, Connecticut • Boston, Massachusetts

Conditions: Obesity, Hypertension
Interventions: SMART; Behavioral
Lead sponsor: Colorado Center for Chronic Care Innovations, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 2
States / cities: Westminster, Colorado

Conditions: Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions: Smartphone Text Messaging, Fitbit Charge HR; Device
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Glaucoma
Interventions: brimonidine 0.15%; Drug
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 35 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sickle Cell Disease, Pulmonary Hypertension
Interventions: Hydroxyurea; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 10 Years to 25 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Stroke
Interventions: Community Health Worker (CHW), usual care and health education brochures every 4 months.; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Hypertension
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, HIV-1-infection
Interventions: Hypertension control through education and monitoring; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Hypertension
Interventions: Dehydrated alcohol, Peregrine System Kit (Sham Procedure); Drug · Device
Lead sponsor: Ablative Solutions, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Birmingham, Alabama • Atlanta, Georgia • Raleigh, North Carolina + 2 more

Conditions: Open Angle Glaucoma
Interventions: Cosopt, Xalatan; Drug
Lead sponsor: Advanced Glaucoma Specialists; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Reading, Massachusetts

Conditions: Cardiovascular Diseases, Heart Diseases, Coronary Disease, Diabetes Mellitus, Atherosclerosis, Cerebral Arteriosclerosis, Hypertension
Interventions: Lifestyle Changes, Antiplatelet Agents, Beta Blocker, ACE Inhibitors; Behavioral · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

Safety and Efficacy of Punctum Plug Delivery System in Subjects With Open-Angle Glaucoma or Ocular Hypertension

A Virtual Reality Platform Simulating Visual Impairment for Testing of Electronic Travel Aids and Performing Orientation and Mobility Training

Comparing NGENUITY vs Conventional Microscope in a New Hydrus User

Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension

Nebivolol Versus Metoprolol: Sodium Sensitivity

6R-BH4 Pulmonary Arterial Hypertension Study

Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis

To Determine Blood Pressure Interaction Between TC-5214 and Anti-Hypertensive Medications (Calcium Channel Blockers, Beta Blockers, and ACE Inhibitors) in Patients With Chronic Hypertension

Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension

Young Adult Hypertension Self-Management Clinical Trial

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

The Short-Term Effect of a Technology Driven Weight Control (SMART) Program for Obese Adults

A Mobile Health Intervention in Pulmonary Arterial Hypertension

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension

Hispanic Secondary Stroke Prevention Initiative

Trans-pulmonary Biomarkers in Pulmonary Hypertension

Addressing Barriers to Anti-hypertensive Medication Adherence Among PLWH Who Have Achieved Viral Suppression

TARGET BP I Clinical Trial

Comparison of Efficacy of Two Groups of Glaucoma Drops (Xalatan vs.Cosopt) in Reducing Eye Pressure Following Laser (SLT)Treatment in the Management of Glaucoma.

Reducing Total Cardiovascular Risk in an Urban Community